-+ 0.00%
-+ 0.00%
-+ 0.00%
BioLineRx And Hemispherian Present Two Posters Featuring GLIX1 At 31st Society For Neuro-Oncology Annual Meeting
Share
Listen to the news

- Fourth cohort initiated in ongoing Phase 1/2a study of GLIX1; remaining cohorts to include patients in window-of-opportunity setting -

- GLIX1 demonstrated robust, dose-dependent antitumor activity in multiple GBM models, including confirmed evidence of brain penetration and dose-dependent increases in tumor 5hmC -

TEL AVIV, Israel and OSLO, Norway, Nov. 16, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two posters featuring GLIX1 were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending